Initial testing of Aplidin by the pediatric pre-clinical testing program

Christopher L. Morton, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine Billups, Malcolm A. Smith

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

Original languageEnglish (US)
Pages (from-to)509-512
Number of pages4
JournalPediatric Blood and Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Heterografts
Appointments and Schedules
Cell Line
aplidine
Growth
In Vitro Techniques

Keywords

  • Aplidin
  • Developmental therapeutics
  • Pre-clinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Morton, C. L., Houghton, P. J., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., ... Smith, M. A. (2009). Initial testing of Aplidin by the pediatric pre-clinical testing program. Pediatric Blood and Cancer, 53(3), 509-512. https://doi.org/10.1002/pbc.21976

Initial testing of Aplidin by the pediatric pre-clinical testing program. / Morton, Christopher L.; Houghton, Peter J.; Gorlick, Richard; Kolb, E. Anders; Lock, Richard; Carol, Hernan; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Billups, Catherine; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 53, No. 3, 09.2009, p. 509-512.

Research output: Contribution to journalArticle

Morton, CL, Houghton, PJ, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Billups, C & Smith, MA 2009, 'Initial testing of Aplidin by the pediatric pre-clinical testing program', Pediatric Blood and Cancer, vol. 53, no. 3, pp. 509-512. https://doi.org/10.1002/pbc.21976
Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H et al. Initial testing of Aplidin by the pediatric pre-clinical testing program. Pediatric Blood and Cancer. 2009 Sep;53(3):509-512. https://doi.org/10.1002/pbc.21976
Morton, Christopher L. ; Houghton, Peter J. ; Gorlick, Richard ; Kolb, E. Anders ; Lock, Richard ; Carol, Hernan ; Keir, Stephen T. ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Billups, Catherine ; Smith, Malcolm A. / Initial testing of Aplidin by the pediatric pre-clinical testing program. In: Pediatric Blood and Cancer. 2009 ; Vol. 53, No. 3. pp. 509-512.
@article{46be7b1da96146d085d8ffb9550a3afb,
title = "Initial testing of Aplidin by the pediatric pre-clinical testing program",
abstract = "Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43{\%}) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.",
keywords = "Aplidin, Developmental therapeutics, Pre-clinical testing",
author = "Morton, {Christopher L.} and Houghton, {Peter J.} and Richard Gorlick and Kolb, {E. Anders} and Richard Lock and Hernan Carol and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Catherine Billups and Smith, {Malcolm A.}",
year = "2009",
month = "9",
doi = "10.1002/pbc.21976",
language = "English (US)",
volume = "53",
pages = "509--512",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Initial testing of Aplidin by the pediatric pre-clinical testing program

AU - Morton, Christopher L.

AU - Houghton, Peter J.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Lock, Richard

AU - Carol, Hernan

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Billups, Catherine

AU - Smith, Malcolm A.

PY - 2009/9

Y1 - 2009/9

N2 - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

AB - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

KW - Aplidin

KW - Developmental therapeutics

KW - Pre-clinical testing

UR - http://www.scopus.com/inward/record.url?scp=67651204923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651204923&partnerID=8YFLogxK

U2 - 10.1002/pbc.21976

DO - 10.1002/pbc.21976

M3 - Article

C2 - 19418543

AN - SCOPUS:67651204923

VL - 53

SP - 509

EP - 512

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -